Sürdürülebilir Kalkınma Amaçları
Yazarlar
- Coskun, Alper(2)
- Majidova, Nargiz(2)
- Unsal, Ahmet(2)
- Acar, Caner(1)
- Akbas, Sinem(1)
- Akyildiz, Arif(1)
- Alan, Ozkan(1)
- Araz, Murat(1)
- Atacan, Huseyin(1)
- Aykan, Musa Baris(1)
- Aytac, Ali(1)
- Bayrakci, Ismail(1)
- Bilici, Ahmet(1)
- Biter, Sedat(1)
- Camanli, Ufuk(1)
- Cicek, Ceren Mordag(1)
- Demir, Teyfik(1)
- Demirciler, Erkut(1)
- Dilek, Mehmet siddik(1)
- Disli, Ahmet Kursat(1)
- Engin, Esra Ozen(1)
- Erdogan, Bulent(1)
- Goker, Erdem(1)
- Gunenc, Damla(1)
- Guren, Ali Kaan(1)
- Guven, Deniz Can(1)
- Gürsoy, Pinar(1)
- Hamitoglu, Buket(1)
- Ilhan, Nurullah(1)
- Kara, Ismail Oguz(1)
- Kara, Mahmut(1)
- Kolkiran, Nagihan(1)
- Koseci, Tolga(1)
- Kostek, Osman(1)
- Kus, Fatih(1)
- Menekse, Serkan(1)
- Mildanoglu, Maral Martin(1)
- Orman, Seval(1)
- Ozdemir, Nuriye(1)
- Ozveren, Ahmet(1)
Yayınlar
- MakaleAçık Erişim2025Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
Majidova, Nargiz; Yaslikaya, Sendag; Mildanoglu, Maral Martin; Coskun, Alper; Uzundal, Duygu Ercan; Sahin, Taha Koray; Akyildiz, Arif; Akbas, Sinem; Camanli, Ufuk; Sahin, Elif
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was to analyze the real-world clinical results of second-line treatments in progression after Atez/Bev and to determine the factors affecting prognosis. Materials and Methods: Fifty-eight patients treated with second-line sorafenib, regorafenib, and cabozantinib for progression after first-line Atez/Bev for advanced/metastatic HCC from 20 centers in T & uuml;rkiye between October 2020 and June 2024 were retrospectively analyzed. Responses were evaluated by Response criteria, specifically Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Median overall survival (OS) and progression-free survival (PFS) were computed with the Kaplan-Meier method. The Cox regression model was utilized to analyze multivariate analyses. Results: About 82.8% of the patients were male and the median age of the whole group was 62 (range, 18-78) years. All patients progressed after first-line Atez/Bev and were given second-line treatment. The most commonly used second-line treatment option was sorafenib (70.7%), followed by regorafenib (12.1%) and cabozantinib (10.3%). Both median PFS (4.1 months) and median OS (7.8 months) were longer in patients treated with sorafenib compared to other treatments. In univariate analyses, Child-Pugh score B, high alpha-fetoprotein (AFP) levels (>200 ng/mL), extrahepatic spread, and Prognostic Nutritional Index (PNI) < 47.6 substantially raised the risk of overall mortality. Multivariate analysis showed that extrahepatic spread (HR (Hazard ratio): 0.41, P = .012), PNI level (HR: 0.24, P = .005), and AFP level (HR:1.97, P = .049) were independent predictors of OS. Conclusion: Although second-line therapies after Atez/Bev show different degrees of efficacy, survival rates are consistent with the literature. Extrahepatic spread, AFP level, and PNI level are the main prognostic factors. In light of this information, personalized treatment strategies may improve outcomes for this challenging patient group.
- MakaleAçık Erişim2025Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study
Tünbekici, Salih; Yuksel, Haydar cagatay; Acar, Caner; Sahin, Goekhan; Orman, Seval; Majidova, Nargiz; Coskun, Alper; Seyyar, Mustafa; Dilek, Mehmet siddik; Kara, Mahmut
Background/Objectives: In the REGOMA trial, regorafenib demonstrated an overall survival advantage over lomustine, and it has become a recommended treatment for recurrent glioblastoma in guidelines. This study aimed to evaluate the effectiveness and safety of regorafenib as a third-line treatment for patients with recurrent glioblastoma who progressed while taking bevacizumab-based therapy. Methods: This retrospective, multicenter study in Turkey included 65 patients treated between 2021 and 2023 across 19 oncology centers. The main inclusion criteria were histologically confirmed isocitrate dehydrogenase (IDH)-wildtype glioblastoma, progression after second-line bevacizumab-based treatment, and an Eastern Cooperative Oncology Group (ECOG) performance status score of <= 2. Patients received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle. Results: The median age of the patients was 53 years (18-67 years), with a median progression-free survival of 2.5 months (95% Confidence Interval: 2.23-2.75) and a median overall survival of 4.1 months (95% CI: 3.52-4.68). The median overall survival was improved in patients who received subsequent therapy after regorafenib treatment compared with those who did not (p = 0.022). Progression-free survival was longer in patients with ECOG 0-1 than in those with ECOG 2 (p = 0.042). The safety profile was consistent with that of the REGOMA trial, with no drug-related deaths observed. Conclusions: Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.